In the August 14 Proceedings of the National Academy of Sciences, Yee Cho and colleagues at the National Institutes of Health, Bethesda, MD, report the use of DNA microarrays to resolve aspects of the ...

Sanofi has tapped Alloy Therapeutics to enable development of a central nervous system drug, agreeing to pay $27.5 million in upfront and near-term fees to access an antisense platform.

In trials at University College London Hospitals (UCLH), an ASO is being used to target the mutated gene that results in the ...

Therapeutic development for Huntington’s disease has largely focused on small molecules and antisense oligonucleotides (ASO). The latter are small strands of RNA or DNA that can be designed to ...

As surprisingly high proportions of eukaryotic genomes are transcribed, with numerous noncoding and antisense RNAs being ... from evolutionarily unrelated DNA is noise, so analysis of cells ...

Equities research analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a report released on Wednesday. The firm set a “sell” rating on the stock.

T De Backer et al created a library of cloned C. albicans DNA fragments, introduced these into C. albicans and screened for the effects of gene suppression on yeast growth. About 10% of transformants ...